{"name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","slug":"suzhou-zelgen-biopharmaceuticals-coltd","ticker":"","exchange":"","domain":"suzhouzelgenbiopharmaceuticals.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"Gecacitinib Hydrochloride Tablets","genericName":"Gecacitinib Hydrochloride Tablets","slug":"gecacitinib-hydrochloride-tablets","indication":"Other","status":"phase_1"},{"name":"CM4307","genericName":"CM4307","slug":"cm4307","indication":"Other","status":"phase_1"},{"name":"Donafenib Tosilate Tablets","genericName":"Donafenib Tosilate Tablets","slug":"donafenib-tosilate-tablets","indication":"Other","status":"phase_1"},{"name":"ZG2001 Tosilate Tablets","genericName":"ZG2001 Tosilate Tablets","slug":"zg2001-tosilate-tablets","indication":"Other","status":"phase_1"},{"name":"ZGGS15","genericName":"ZGGS15","slug":"zggs15","indication":"Other","status":"phase_1"},{"name":"Alkotinib","genericName":"Alkotinib","slug":"alkotinib","indication":"Other","status":"phase_1"},{"name":"Jaktinib","genericName":"Jaktinib","slug":"jaktinib","indication":"Other","status":"phase_3"},{"name":"Placebo to match Hydroxycarbamide","genericName":"Placebo to match Hydroxycarbamide","slug":"placebo-to-match-hydroxycarbamide","indication":"Control arm in Phase 3 clinical trials (indication depends on the active hydroxycarbamide trial)","status":"phase_3"},{"name":"Placebo to match Jaktinib","genericName":"Placebo to match Jaktinib","slug":"placebo-to-match-jaktinib","indication":"Control arm in Phase 3 clinical trials of Jaktinib (indication determined by parent drug trial)","status":"phase_3"},{"name":"ZG005","genericName":"ZG005","slug":"zg005","indication":"Other","status":"phase_2"},{"name":"ZG19018","genericName":"ZG19018","slug":"zg19018","indication":"Other","status":"phase_1"},{"name":"[14C]-Jaktinib","genericName":"[14C]-Jaktinib","slug":"14c-jaktinib","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ZG006","genericName":"ZG006","slug":"zg006","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Hydroxycarbamide Tablets","genericName":"Hydroxycarbamide Tablets","slug":"hydroxycarbamide-tablets","indication":"Sickle cell disease","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Rifampicin Capsules","genericName":"Rifampicin Capsules","slug":"rifampicin-capsules","indication":"Tuberculosis (pulmonary and extrapulmonary)","status":"marketed"}]}],"pipeline":[{"name":"Gecacitinib Hydrochloride Tablets","genericName":"Gecacitinib Hydrochloride Tablets","slug":"gecacitinib-hydrochloride-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CM4307","genericName":"CM4307","slug":"cm4307","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Donafenib Tosilate Tablets","genericName":"Donafenib Tosilate Tablets","slug":"donafenib-tosilate-tablets","phase":"phase_1","mechanism":"Donafenib inhibits multiple receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis.","indications":[],"catalyst":""},{"name":"ZG006","genericName":"ZG006","slug":"zg006","phase":"phase_3","mechanism":"ZG006 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"ZG2001 Tosilate Tablets","genericName":"ZG2001 Tosilate Tablets","slug":"zg2001-tosilate-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZGGS15","genericName":"ZGGS15","slug":"zggs15","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Alkotinib","genericName":"Alkotinib","slug":"alkotinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hydroxycarbamide Tablets","genericName":"Hydroxycarbamide Tablets","slug":"hydroxycarbamide-tablets","phase":"phase_3","mechanism":"Hydroxycarbamide inhibits ribonucleotide reductase, reducing deoxynucleotide synthesis and promoting fetal hemoglobin production while decreasing sickling and hemolysis.","indications":["Sickle cell disease","Chronic myeloid leukemia","Polycythemia vera","Essential thrombocythemia"],"catalyst":""},{"name":"Jaktinib","genericName":"Jaktinib","slug":"jaktinib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo to match Hydroxycarbamide","genericName":"Placebo to match Hydroxycarbamide","slug":"placebo-to-match-hydroxycarbamide","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration of hydroxycarbamide for use as a control in clinical trials.","indications":["Control arm in Phase 3 clinical trials (indication depends on the active hydroxycarbamide trial)"],"catalyst":""},{"name":"Placebo to match Jaktinib","genericName":"Placebo to match Jaktinib","slug":"placebo-to-match-jaktinib","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration of Jaktinib, a JAK inhibitor, for use as a control in clinical trials.","indications":["Control arm in Phase 3 clinical trials of Jaktinib (indication determined by parent drug trial)"],"catalyst":""},{"name":"Rifampicin Capsules","genericName":"Rifampicin Capsules","slug":"rifampicin-capsules","phase":"marketed","mechanism":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.","indications":["Tuberculosis (pulmonary and extrapulmonary)","Leprosy","Atypical mycobacterial infections","Prophylaxis of meningococcal meningitis","Brucellosis"],"catalyst":""},{"name":"ZG005","genericName":"ZG005","slug":"zg005","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ZG19018","genericName":"ZG19018","slug":"zg19018","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-Jaktinib","genericName":"[14C]-Jaktinib","slug":"14c-jaktinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":15,"phaseCounts":{"phase_1":8,"phase_3":5,"marketed":1,"phase_2":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}